AstraZeneca plans to construct a $1.5 billion manufacturing plant in Singapore to provide a promising category of cancer drugs called antibody-drug conjugates (ADCs), the Anglo-Swedish drugmaker said on Monday.
The facility will likely be supported by the Singapore Economic Development Board. The company didn’t provide details on possible financial incentives from the Singapore government.
The statement added that the ability will likely be AstraZeneca’s first facility dedicated to end-to-end drug conjugate manufacturing.
Drug-antibody conjugates have change into a vital a part of Astra’s cancer campaign, offering hope that they might eventually replace conventional chemotherapy for some patients. They work by transferring the lively ingredient on to cancer cells, while sparing healthy ones.
The plant is a “strong demonstration of confidence in Singapore’s biopharmaceuticals capabilities and talent,” said Png Cheong Boon, chairman of the Singapore Economic Development Council.
CEO Pascal Soriot is working to make sure Astra can independently supply medicines to major markets because the United States seeks to scale back the industry’s dependence on China. Shortages throughout the pandemic have also highlighted the necessity for local production.
London-listed AstraZeneca has entered markets reminiscent of China, Indonesia and India over the past few years because it seeks to expand its supply chain. Enhertu’s breast cancer therapy is led by her partner Daiichi Sankyo in Japan.
Soriot said Singapore is a world-leading investment destination and has a popularity for excellence in complex manufacturing.
ADCs are modified antibodies that bind to cancer cells after which release chemicals that kill the cells.
The multi-stage production of ADC involves the production of an antibody, the synthesis of a chemotherapeutic drug and its linker, conjugation of those elements and filling with a ready-made ADC substance.
AstraZeneca has a broad pipeline of proprietary ADCs, which incorporates six wholly owned ADCs in clinical development and more in preclinical development.
Png welcomed AstraZeneca’s plans, saying they support the event and manufacturing of precision medicines in Singapore and help create jobs and economic opportunities.
Construction of the ability will begin at the tip of 2024, and the ability must be operational in 2029, the corporate said, adding that it can have zero carbon dioxide emissions from the primary day of operation.
